| [ Summary ] |
It has been over a decade since gemcitabine was introduced into chemotherapy for advanced pancreatic cancer, and many combination therapies that include gemcitabine have since been developed. While the combination of gemcitabine with erlotinib has been shown to be effective, it has not yet become standard therapy. FOLFIRINOX 〔5-fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin〕, a combination therapy that does not include gemcitabine, was reported in 2010 to be effective and has garnered attention. In Japan, phase III trials including S-1 are being conducted. OFF (5-FU, folinic acid, and oxaliplatin) has been reported to be effective as second-line chemotherapy in patients refractory to gemcitabine. For adjuvant chemotherapy following radical resection, adjuvant gemcitabine has been shown to be more effective than resection alone and has been accepted as a standard of care. |